CardioCell To Pursue Large-Scale Chronic Heart Failure Trial For IV Stem Cell Therapy
CardioCell has presented data from the first clinical trial to demonstrate the safety and viability of intravenous (IV) ischemia-tolerant mesenchymal stem cells in chronic heart failure patients – dispelling the theory that only large amounts of stem cells delivered directly to the myocardium would achieve improvements in patient outcomes.
You may also be interested in...
Topline data from the SOCRATES trial of Brilinta (Brilique; ticagrelor) provided more ammunition for those pushing for AstraZeneca's CEO Pascal Soriot to have his pay linked to performance.
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.